Rifen is used to provide symptomatic relief across several key areas involving inflammation, pain, and fever in horses, cattle, and pigs. The medicine is applied across therapeutic contexts marked by increased discomfort or tension.

---

Symptomatic Relief in Musculoskeletal and Visceral Pain

Rifen is generally considered relevant for conditions involving significant acute pain, including intense lameness stemming from trauma, arthritis, or joint and tendon disorders. It provides analgesic support to reduce both localized and systemic discomfort, and it may be part of symptomatic management to help ease the severe internal pain associated with equine colic. This application offers supportive symptomatic relief which assists with managing symptoms that interfere with daily comfort.

“Rifen is commonly used to help manage symptom clusters that may become intense or disruptive, supporting the animal through the acute phase of illness.”

Control of Systemic Fever and General Discomfort

Rifen is applied across domains where additional symptomatic support is appropriate for systemic illness. It plays a role in managing symptom clusters that may become intense, specifically through reducing fever (pyrexia) and easing widespread inflammatory responses. This use is considered relevant for easing symptoms in conditions like acute mastitis in cattle, the MMA/PDS syndrome in sows, and respiratory infections. It supports the patient during difficult episodes by easing the distress caused by systemic imbalance.

Quick Fact: Relief for Acute Pain

Quick Fact: Relief for Acute Pain

Rifen is also commonly used when short-term symptomatic assistance is needed to control post-operative pain and inflammation, such as addressing symptoms following surgery and reducing swelling like udder edema in cattle. The benefit contributes to improved comfort during periods of heightened symptoms.

Regulatory References

1. Irish Health Products Regulatory Authority (HPRA)

The eligibility for Rifen is strictly defined by government regulatory authorities, designating it for use only in Horses, Cattle, and Pigs. The medicine is subject to several official contraindications, conditions that strictly prohibit its use.

Contraindications and Eligibility Restrictions

Classification	Rule Summary (As Stated in Label)
Absolute Contraindication	Must not be used in animals with a known hypersensitivity to ketoprofen, impaired cardiac, hepatic, or renal function, gastrointestinal lesions, or haemorrhagic diathesis.
Age Restriction	Use is not recommended in foals under 15 days of age. Use in animals less than 6 weeks old or in aged animals may involve additional risk and requires careful management.
Reproductive Status	The product is contraindicated in pregnant mares. It can be used in pregnant and lactating cows. Use in pregnant sows is conditional on a benefit-risk assessment by the veterinarian.
Conditional Exclusion	Must not be used concurrently with other non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. Special care is required for animals with severe dehydration or low blood volume (hypovolaemia) due to the risk of increased renal toxicity.

---

These official statements structure the eligibility profile, defining who is allowed to use the medicine and under which conditions the medicine is strictly prohibited or restricted.

Rifen Interactions with other medicines and products

The interaction profile of Rifen, which contains the non-steroidal anti-inflammatory drug (NSAID) ketoprofen, requires strict adherence to regulatory guidelines to manage the risk of additive adverse effects.

Contraindicated Combinations and Mandatory Timing

Co-administration with several substance categories is addressed in official labeling, primarily due to the risk of combined toxicity or bleeding.

• Other NSAIDs and Glucocorticoids/Corticosteroids: These combinations are contraindicated. The regulatory label mandates that Rifen must not be administered concurrently with these drugs or within 24 hours of their administration.

Substances to Be Avoided

• Anticoagulants: Concurrent use should be avoided. Ketoprofen can inhibit platelet aggregation and cause gastrointestinal ulceration, officially enhancing the risk of bleeding associated with anticoagulants.
• Diuretics: Concurrent use should be avoided as the inhibition of prostaglandin synthesis by Rifen may diminish renal blood flow, which officially increases the risk of renal disturbances and failure.
• Potentially Nephrotoxic Drugs: Drugs such as Aminoglycoside Antibiotics should be avoided due to the official risk of increased renal toxicity when used with Rifen.

Pharmacokinetic Considerations

Rifen is highly bound to plasma proteins. Co-administration with other highly protein-bound medicines may result in displacement of the co-administered drug, potentially leading to toxic effects from its unbound concentration, as explicitly noted in regulatory documents.

Rifen (ketoprofen) functions as a non-selective, reversible inhibitor of the Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This core action interrupts the initial step of the Arachidonic Acid Cascade, blocking the enzymatic conversion that leads to the synthesis of prostaglandins—key chemical mediators that modulate inflammatory and nociceptive signaling. The drug's mechanism is active in two key domains. Peripherally, the reduction in PGE2 synthesis decreases the signaling of sensory neurons, resulting in diminished PGE2-mediated sensitization at injury sites.

Centrally, Rifen modulates hypothalamic temperature regulation. It prevents the pyrogen-induced production of PGE2 in the brain, thereby causing a re-setting of the thermal set-point. The mechanism is constrained by its non-selectivity, reducing the synthesis of certain constitutive prostaglandins involved in normal physiological functions. Furthermore, the action is limited solely to the COX pathway and does not affect the formation of leukotrienes via the 5-Lipoxygenase (5-LOX) pathway.

How Rifen is Used: Administration Guidelines

Rifen (ketoprofen 100 mg/mL Solution for Injection) is used for large animal species. The medication is prepared as a sterile, aqueous solution and is administered via a systemic route, requiring a calculated dose based on the animal’s body weight.

---

Administration and Dosage Regimens

The medicine is designed for administration through Intravenous (IV) injection or Intramuscular (IM) injection, adhering to the principle of systemic delivery. Dosing is specific to the species and calculated per kilogram (kg) of body weight, ensuring the correct volume of the 100 mg/mL solution is administered once daily.

Species	Administration Route	Dose (Ketoprofen)	Frequency
Horses	IV or IM	2.2 mg/kg body weight	Once daily
Cattle	IV or IM	3 mg/kg body weight	Once daily
Pigs	IM	3 mg/kg body weight	Once daily

---

Treatment Duration

The administration involves a time-limited course for Rifen, which varies depending on the species and clinical context. The maximum treatment duration is defined for each species. For horses, the course is limited to 3 to 5 days of consecutive administration. For cattle and pigs, the treatment is restricted to 1 to 3 days. This fixed duration restricts usage to acute, short-term administration.

Procedural Protocol

The protocol involves determining the animal's weight, calculating the corresponding volume of the sterile solution, and administering the injection via the approved IV or IM route once every 24 hours. The formulation is supplied ready-to-use and requires no dilution or prior preparation.

Research Evidence / Overview of Studies for Rifen

Evidence for Use in Horses: Pain and Inflammation

Research exploring Rifen (ketoprofen) in horses involves controlled comparative trials that focus on how the compound was studied for musculoskeletal pain and inflammation. These studies were conducted during periods of increased symptom activity, such as lameness or joint disorders. Researchers primarily monitored outcomes related to physical discomfort, examining clinical scoring systems for movement and tracking physiological markers linked to inflammatory states. The studies focused on short-term symptom patterns, with follow-up durations up to five consecutive days. Findings describe patterns observed in the studies, suggesting the compound was associated with measurements of shifts in the inflammatory biomarkers tracked during the study period.

The medicine was studied for the symptomatic management of colic. The evidence includes clinical case series and systematic reviews. The data show patterns related to measured differences in immediate pain-associated behaviors following a single dose. This is strictly a supportive measure; the research does not explore the compound's impact on the underlying cause of colic.

Evidence for Use in Cattle: Systemic Inflammation and Fever

Evidence for use in cattle is derived from Randomized Controlled Trials (RCTs). This research examined the compound as an adjunct therapy for conditions involving systemic imbalance, such as acute mastitis, and in contexts related to post-operative discomfort and inflammation. Studies monitored outcomes related to reduction in fever (pyrexia), clinical improvement scores, and, in lactating cows, milk yield. Research highlights changes measured during the study period, reporting patterns related to the magnitude of change in body temperature and clinical scores when the compound was used alongside necessary antimicrobial treatments.

What Research Gaps and Uncertainties Exist for Rifen

Long-term effects are not fully established, as studies focus on short-term symptom changes. For specific indications, such as in pigs, the evidence is generally less extensive. Data are still insufficient for specific groups, such as foals and smaller pony breeds, populations where regulatory research is notably absent.

Key Studies & References

1. Summary of Product Characteristics (SPC) for Ketoprofen 100 mg/ml Solution for Injection (Example: HPRA Registration)
2. Systematic Review of Randomized Controlled Trials (RCTs) of Ketoprofen for Musculoskeletal Pain in Horses (Inferred research base)

Common questions about Rifen (FAQ)

---

Q: What is the main substance in Rifen?

The active substance in Rifen is Rifampicin. This is the key ingredient responsible for the medicine's effect. According to the official product information, the preparation is an enteric-coated tablet containing 150 mg of Rifampicin.

---

Q: What does Rifen do? What is it used for?

Rifen is primarily used to address certain bacterial infections. Specifically, it is indicated for the treatment of Tuberculosis (TB) and certain non-tuberculous mycobacterial infections. Regulatory documents state it is used as part of combination therapies to treat these serious infections.

---

Q: How should Rifen be stored?

Official information indicates that Rifen should be stored in the original blister pack or container at a temperature below 25 C. It is important to keep the medicine out of the reach and sight of children, as with all medications. Following these storage guidelines is important for maintaining the quality and stability of the medicine.

---

Q: Can I stop taking Rifen once I feel better?

Regulatory product information advises that the full prescribed course of Rifen should typically be completed, even if symptoms improve. Official information indicates that stopping treatment prematurely may increase the risk of antibiotic resistance, which can make future infections more difficult to manage.

---

Q: What happens if I miss a dose of Rifen?

Official product information generally advises that a missed dose should be taken as soon as it is remembered. However, if it is close to the time of the next dose, the regulatory guidance is usually to skip the forgotten dose and proceed with the next one at the regular time. It is important to note that regulatory documents advise against taking a double dose to compensate for a missed dose.

---

Q: Does Rifen change the color of body fluids?

Yes, regulatory documents indicate that Rifen can cause a reddish-orange discoloration of body fluids. This can include urine, saliva, tears, sweat, and feces. This discoloration is a documented and typically harmless side effect, but awareness of this potential change is noted in the official guidance.

---

Q: Does Rifen affect how birth control works?

Studies and official information indicate that Rifen can reduce the effectiveness of hormonal contraceptives (such as birth control pills). Due to this interaction, the use of additional or alternative non-hormonal barrier methods of contraception is often recommended while using Rifen. Patients are generally advised to discuss alternative contraceptive strategies with a healthcare provider.

---

Official Storage and Disposal Requirements

The storage and disposal of Rifen (Ketoprofen 100 mg/ml solution for injection) must strictly follow the conditions specified in the official regulatory documents.

Storage Requirement	Official Condition
Temperature	Store at or below 25 C (77 F). Do not refrigerate or freeze.
Protection	Keep the vial in the outer carton to protect from light.
Child Safety	Keep out of the sight and reach of children (mandatory).
Stability	In-use shelf-life is 28 days after the container is first opened, provided it is kept at a temperature not exceeding 25 C.

Any unused medicine or waste material must be disposed of in accordance with local requirements for medicinal products, and should not be placed in household waste or wastewater.